Avacta Group PLC (AVCT)
London Exchange · UK · prices in GBX · close of 22 Oct 2026
Key indicators
| Last close | GBX 64.10 |
|---|---|
| 52-week range | 48.00 – 92.00 |
| Return, 1 month / 3 months | −14.5% / −5.7% |
| Return, 1 year / 3 years | +0.2% / −50.7% |
| Trend | Below its 200-day average |
| RSI (14) | 38 |
| Volatility (1 year) | 54.7% |
| Worst drawdown (1 year) | -40.0% |
| Average daily value traded | 101.12M GBX |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Avacta Group is a life sciences company based in the United Kingdom that develops and supplies tools and technologies for research and healthcare. Its work centres on Affimer proteins, a class of engineered binding proteins used as alternatives to antibodies in diagnostics and therapeutic development. The company also provides reagents, assays and related services to laboratories and life science researchers, and it is developing its own therapeutic candidates for use in oncology and other disease areas.
On this site Avacta Group PLC appears as a stock on the London Exchange (UK), code AVCT, with prices in pence sterling (GBX). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Avacta Group PLC (AVCT) trades on the London Exchange in UK. It last closed at GBX 64.10 on 22 October 2026.
Its price-based Market X-Ray is 45 out of 100 (a weak price profile), ranking 2,342 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 0.2% and over the last three months it fell 5.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 39 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -6.5% | ||
| From 52-week high | -28.0% | ||
| Momentum | 43 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -5.7% | ||
| 6-month return | -14.5% | ||
| 12-month return, skipping the last month | 17.2% | ||
| Stability (higher is calmer) | 27 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 54.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -40.0% | ||
| Liquidity | 89 · Strong | Trades actively. | |
| Average daily value traded | 101.12M GBX | ||
| Zero-volume days | 5.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −1.4% |
|---|---|
| 1 month | −14.5% |
| 3 months | −5.7% |
| 6 months | −14.5% |
| 1 year | +0.2% |
| 3 years | −50.7% |
| 5 years | −47.4% |
Signals
| 50-day / 200-day average | 69.36 / 68.58 |
|---|---|
| Golden / death cross (60 days) | Golden, 26 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 3.36 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.